Bictegravir/lenacapavir
From Wikipedia, the free encyclopedia
| Combination of | |
|---|---|
| Bictegravir | Integrase inhibitor |
| Lenacapavir | Capsid inhibitor |
| Legal status | |
| Legal status |
|
Bictegravir/lenacapavir is an experimental combination drug under investigation for the treatment of HIV-1.
It is being developed by Gilead Sciences and has completed Phase III trials in late 2025.[1][2][3] The drug is a combination of two other anti-HIV medications from Gilead, bictegravir and lenacapavir.
